Company Overview and News

3
Aurinia Pharmaceuticals: Clear Winner In Lupus Nephritis

2018-10-02 seekingalpha - 2
Aurinia Pharmaceuticals (AUPH) has a small pipeline with just a single drug, Voclosporin, in 3 indications. The most advanced, Lupus nephritis or LN, is in early phase 3; the other two are too early to be considered for evaluation.
AUP AUPH

2
Kane Biotech Announces Formation of Scientific Advisory Board

2018-09-24 globenewswire - 1
WINNIPEG, Manitoba, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced the formation of a Scientific Advisory Board (SAB), chaired by Kane Biotech Board Director Rivka Gluck, and will work closely with senior management to advance the Company’s integration and scope of clinical applications of its patented anti-microbial technology.
AUP KNBIF AUPH KNE

3
Aurinia And Voclosporin: Making A Difference In Focal Segmental Glomerulosclerosis

2018-09-24 seekingalpha - 1
Voclosporin is an immunosuppressive/anti-inflammatory investigative drug candidate in clinical trials for lupus nephritis, dry eye syndrome as well as focal segmental glomerulosclerosis, the focus of this article.
AUP CCXI RTRX AUPH

21
2018 Is An Ideal Entry Point For Aurinia Pharmaceuticals

2018-09-10 seekingalpha - 4
Voclosporin is in Phase III trials for treatment of lupus nephritis (LN) and has a high probability of FDA approval based on Phase IIb data.
SHPG 524715 AUP AGN AZN SUNPHARMA AUPH ABBV ACT GSK

28
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany

2018-09-03 seekingalpha
Discussion: AstraZeneca (AZN) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE). The drug failed to achieve a statistically valid reduction in disease activity at month 12 as measured by a scale called SRI4. Reduction in SRI4 value was the primary endpoint of the trial. Shares slipped marginally by 1% in the negative news.
VRTX QDEL AQST AZN PTLA AUPH ARWR CRSP GSK CADILAHC CDLYY MYL 532321 AUP AZN IMMU BMS JNJ BGNE NVS

3
Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha - 2
Greetings. Welcome to Aurinia Pharmaceuticals Incorporated Q2 2018 Financial Results. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
AUP AUPH

3
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks - 2
Aurinia Pharmaceuticals (AUPH - Free Report) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.
PLNT GD AUP AUPH EPE

7
Take Advantage Of Poor Market Sentiment And Buy Esperion Therapeutics

2018-07-17 seekingalpha - 5
Bempedoic Acid will be a winner in the LDL-C reduction and cardiovascular disease prevention markets, as both a monotherapy and add-on to existing treatments.
AUP CVD BBAGF AUPH ESPR

7
Aurinia Pharmaceuticals Has Lots of Upside Potential

2018-07-13 investorplace - 6
Since last year, Aurinia Pharmaceuticals (NASDAQ:AUPH) has moved very little on the stock market. It is now in a holding pattern, in the range of $4.50 to $6. News of the launch of a mid-stage study, along with a quarterly earnings report before that, failed to ignite or hurt AUPH stock by much. Yet both events suggest that the company is on the right path.
AUP AGN AUPH

33
Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

2018-07-13 seekingalpha
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
SNWW AST ACHV URGN CDXC OVID AUPH SNWV DRNA AKCA TORC AUP OSIR AGN MRK IONS NVS ABBV RMD BMY ABBV

30
Your Daily Pharma Scoop: IPO Review - Aptinyx Surges, Kezar Progresses, Neon Slumps

2018-07-11 seekingalpha - 2
Aptinyx (APTX) priced its IPO at $16.00. 6.4M common stock shares were offered. Additional 959,999 shares were on underwriters over-allotment. Gross proceeds initially expected was ~102.4M, but reached $117.8M by the time of closing. The shares opened at $17.40 on June 21. The IPO closed on June 25.
GLENMARK APTX ALPMF AUPH DEPO LLY GSK GLKQY CADILAHC CDLYY 4503 MYL 532321 ALPMY AUP NTGN IMMU BMS 532296 JNJ NVS KZR PFE

290
BioSpace Movers and Shakers for Week of June 4th

2018-06-12 biospace - 4
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors. The companies filled the roles with the talent they believe will drive the next stage of growth.
AUP EVFM PTLA AUPH DARE SRPT TRIL

249
Kane Biotech Appoints Pharmaceutical Executive Rashieda Gluck to Board of Directors

2018-05-22 globenewswire - 2
WINNIPEG, Manitoba, May 22, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce it has appointed Rashieda (Rivka) Gluck to the Corporation’s Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development.
AUP KNBIF AUPH KNE

248
Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha - 1
Greetings and welcome to the Aurinia Pharmaceuticals Q1 2017 Financial Results. At this time, all participants are in a listen only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
AUP AUPH

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:AUP / Aurinia Pharmaceuticals on message board site Silicon Investor.

Hauppauge Digital, Inc. (HAUP) Hauppauge Digital, Inc. (HAUP) Hauppauge Digital, Inc. (HAUP) Dauphin Technology Dauphin Technology Dauphin Technology
HAUP - Hauppauge Digital HAUP - Hauppauge Digital HAUP - Hauppauge Digital HAUP: Hauppauge Digital, Inc. HAUP: Hauppauge Digital, Inc. HAUP: Hauppauge Digital, Inc.